Tumour biology

#Cancer immunotherapies #Cancer research #Dendritic cells #Icahn School of Medicine at Mount Sinai #Tumour biology

Dendritic cells found to organise cancer-fighting immune hubs 

Researchers at the Icahn School of Medicine at Mount Sinai have identified a specialised immune cell that builds and maintains powerful immune hubs inside tumours, a discovery that could help improve the effectiveness of cancer immunotherapies.  The findings, published in Science, show that dendritic cell type 1 is essential for… Read More

#News

#Cancer drug targets #Clinical trial #DNA #Kairos Pharma #Prostate cancer #Stem cells #Tumour biology

Cancer drug resistance isn’t one problem, it’s many

Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it.  Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More

#Cancer Research #Exclusive Content

Neuroendocrine tumours
#Clinical trial #Tumour biology

Trial launched to evaluate neuroendocrine tumour vaccine 

A Phase II trial evaluating a treatment for metastatic neuroendocrine tumours (NETs) has been launched.  SurVaxM, a peptide vaccine, has been developed by biotechnology company MimiVax and will be evaluated in a study conducted at Rosewell Park, New York.  The trial will evaluate SurVaxM in combination with temozolomide… Read More

#Cancer Research #News

#Cancer research #Oncology #T cell #Tumour biology #Tumour microenvironment (TME)

The missing link in treating cancer

Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this aggressive cancer.  For years, the conversation around pancreatic cancer has focused on the tumour itself, the “broken” cells that won’t stop… Read More

#Exclusive Content

#Brain cancer #Spain #Tumour biology

Study identifies new target in brain metastasis 

A new study into brain metastasis has identified an immune target with translational potential.  The study, conducted by researchers at the Spanish National Cancer Research Centre (CNIO), has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. Read More

#Cancer Research #News

Cancer immunotherapy
#Asgard Therapeutics #Biotech #Cancer immunotherapy #Tumour biology

Gene-based immunotherapy could reprogramme tumour cells 

Biotechnology company Asgard Therapeutics is set to announce preclinical results showing its gene-based cancer immunotherapy could reprogramme tumour cells.  The company will present data on AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May in Boston,… Read More

#News

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

#Cancer research #Immune response #Tumour biology

Novel therapy could slow tumour growth, results find 

A novel cancer therapy targeting tumour acidity could boost immune response and slow cancer growth, studies show.  Biotechnology company Dyve Biosciences, in collaboration with Moffitt Cancer Center, reported results for a first-of-its-kind investigational therapy applied to the skin, which is designed to work throughout the body to target the tumour microenvironment –… Read More

#Cancer Research #News

Patient using a mammography machine
#Breast cancer #Tumour biology #University of California San Diego

Discovery sheds light on new way to treat breast cancer 

A new discovery into how breast cancer spreads could pave the way for a new treatment.  Researchers at the University of California San Diego found an inflammatory protein, TYK2, is involved in the process by which cells sense and respond to their physical environment, known as mechanotransduction.  … Read More

#Cancer Research #News

#Brain #Institute of Cancer Research #Tumour biology

Brain imaging platform could ‘accelerate’ tumour treatment 

An advanced imaging platform could “accelerate” the treatment of childhood brain tumours, research reveals.  Scientists at The Institute of Cancer Research, London have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen… Read More

#Cancer Research #News

Colorectal cancer
#Colorectal cancer #Gene mutation #Tumour biology

Gene mutation accelerates tumour growth in colorectal cancer 

A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests.  A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More

#Cancer Research #News

#Cancer research #Drug development #Drug discovery #Immune system #Immunotherapy #Life sciences #Lithuania #Oncology #Start-ups #Tumour biology #Tumours

New podcast: Exciting start-ups and developments in drug discovery

This is the latest episode of the free DDW narrated podcast, titled ‘Exciting start-ups and developments in drug discovery’, which covers two articles written for DDW Volume 24 – Issue 1, Winter 2022/2023. They are called: ‘What Lithuania offers life sciences start-ups’ and ‘… Read More

#News

Cancer cells
#Aprea Therapeutics #Cancer research #Clinical trials #Solid tumours #Tumour biology

Cancer therapy innovation to overcome traditional limitations 

DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance.  MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies… Read More

#Cancer Research #Exclusive Content

#Antibodies #Cancer #Cancer research #Diagnostics #Drug discovery #Fibroblasts #Flow Cytometry #Immunology #Oncology #Tumour biology

Podcast: Flow cytometry for drug discovery research

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging… Read More

#News